High agreement between whole slide imaging and optical microscopy for assessment of HER2 expression in breast cancer. Whole slide imaging for the assessment of HER2 expression.

Pathology Research and Practice

Volumn 210, Issue 11, 2014, Pages 713-718

  Nunes, Cristiana ^a   Rocha, Rafael ^b   Buzelin, Marcelo ^a   Balabram, Débora ^a   Foureaux, Fernanda ^a   Porto, Simone ^a   Gobbi, Helenice ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Breast cancer; Digital pathology; HER2; Immunohistochemistry; Whole slide image

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CB11; MONOCLONAL ANTIBODY SP3; UNCLASSIFIED DRUG; CANCER ANTIBODY; TUMOR MARKER;

ANALYTICAL EQUIPMENT; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL IMAGING; DUAL COLOR IN SITU HYBRIDIZATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MICROSCOPE; MICROSCOPY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; WHOLE SLIDE IMAGING; BREAST TUMOR; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; FEMALE; IMMUNOLOGY; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; TISSUE MICROARRAY; VALIDATION STUDY;

ANTIBODIES, NEOPLASM; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DIAGNOSTIC IMAGING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS;

EID: 84908669709     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.06.031     Document Type: Article

References (43)

1. Al-Janabi S., Huisman A., Willems S.M., Van Diest P.J. Digital slide images for primary diagnostics in breast pathology: a feasibility study. Hum. Pathol. 2012, 43:2318-2325.
2. Camp R.L., Charaette L.A., Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 2000, 80:1943-1949.
3. Chen Y., Liang C.P., Liu Y., Fischer A.H., Parwani A.V., Pantanowitz L. Review of advanced imaging techniques. J. Pathol. Inform. 2012, 3:22.
4. Costello S.S., Johnston D.J., Dervan P.A., O'Shea D.G. Development and evaluation of the WSI pathology slide: a new tool in telepathology. J. Med. Internet Res. 2003, 5:e11.
5. Dolled-Filhart M.P., Gustavson M.D. Tissue microarrays and quantitative tissue-based image evaluation as a tool for oncology biomarker and diagnostic development. Expert Opin. Med. Diagn. 2012, 6:569-583.
6. Ellis I.O., Bartlett J., Dowsett M., Humphreys S., Jasani B., Miller K., Pinder S.E., Rhodes A., Walker R. Best Practice No 176: updated recommendations for HER2 testing in the UK. J. Clin. Pathol. 2004, 57:233-237.
7. Gavrielides M.A., Gallas B.D., Lenz P., Badano A., Hewitt S.M. Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy. Arch. Pathol. Lab. Med. 2011, 135:233-242.
8. Gouvêa A.P., Milanezi F., Olson S.J., Leitao D., Schmitt F.C., Gobbi H. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl. Immunohistochem. Mol. Morphol. 2006, 14:103-108.
9. Gustavson M.D., Bourke-Martin B., Reilly D., Cregger M., Williams C., Mayotte J., Zerkowski M., Tedeschi G., Pinard R., Christiansen J. Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative evaluation. Arch. Pathol. Lab. Med. 2009, 133:1413-1419.
10. Hammond M.E. ASCO-CAP guidelines for breast predictive factor testing: an update. Appl. Immunohistochem. Mol. Morphol. 2011, 19:499-500.
11. Hedvat C.V. Digital microscopy: past, present, and future. Arch. Pathol. Lab. Med. 2010, 134:1666-1670.
12. Ho J., Parwani A.V., Jukic D.M., Yagi Y., Anthony L., Gilbertson J.R. Use of whole slide imaging in surgical pathology quality assurance: Design and pilot validation studies. Hum. Pathol. 2006, 37:322-331.
13. accessed 30.10.13. http://www.vassarstats.net/.
14. Jara-Lazaro A.R., Thamboo T.P., Teh M., Tan P.H. Digital pathology: exploring its applications in diagnostic surgical pathology practice. Pathology 2010, 42:512-518.
15. Joshi A.S., Sharangpani G.M., Porter K., Keyhani S., Morrison C., Basu A.S., Gholap G.A., Gholap A.S., Barsky S.H. Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A 2007, 71:273-285.
16. Keay T., Conway C.M., O'Flaherty N., Hewitt S.M., Shea K., Gavrielides M.A. Reproducibility in the automated quantitative assessment of HER2/neu for breast cancer. J. Pathol. Inform. 2013, 4:19.
17. Koh Y.W., Lee H.J., Lee J.W., Kang J., Gong G. Dual-colour silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod. Pathol. 2011, 24:794-800.
18. Kondo Y., Iijima T., Noguchi M. Evaluation of immunohistochemical staining using whole-slide imaging for HER2 scoring of breast cancer in comparison with real glass slides. Pathol. Int. 2012, 62:592-599.
19. Krenacs T., Zsakovics I., Diczhazi C., Ficsor L., Varga V.S., Molnar B. The potential of digital microscopy in breast pathology. Pathol. Oncol. Res. 2009, 15:55-58.
20. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
21. Laurinaviciene A., Dasevicius D., Ostapenko V., Jarmalaite S., Lazutka J., Laurinavicius A. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays. Diagn. Pathol. 2011, 6:87.
22. Masmoudi H., Hewitt S.M., Petrick N., Myers K.J., Gavrielides M.A. Automated quantitative assessment of HER-2/neu immunohistochemical expression in breast cancer. IEEE Trans. Med. Imaging 2009, 28:916-925.
23. Nassar A., Cohen C., Agersborg S.S., Zhou W., Lynch K.A., Albitar M., Barker E.A., Vanderbilt B.L., Thompson J., Heyman E.R., Lange H., Olson A., Siddiqui M.T. Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens. Arch. Pathol. Lab. Med. 2011, 7:896-902.
24. Nassar A., Cohen C., Agersborg S.S., Zhou W., Lynch K.A., Barker E.A., Vanderbilt B.L., Thompson J., Heyman E.R., Olson A., Lange H., Siddiqui M.T. A multisite performance study comparing the reading of immunohistochemical slides on a computer monitor with conventional manual microscopy for estrogen and progesterone receptor analysis. Am. J. Clin. Pathol. 2011, 3:461-467.
25. Nassar A., Cohen C., Albitar M., Agersborg S.S., Zhou W., Lynch K.A., Heyman E.R., Lange H., Siddiqui M.T. Reading immunohistochemical slides on a computer monitor - a multisite performance study using 180 HER2-stained breast carcinomas. Appl. Immunohistochem. Mol. Morphol. 2011, 3:212-217.
26. Nunes C.B., Rocha R.M., Buzelin M.A., Balabram D., de Souza Foureaux F., Porto S.S., Gobbi H. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma. J. Clin. Pathol. 2013, 18. [Epub ahead of print].
27. Nunes C.B., Rocha R.M., Reis-Filho J.S., Lambros M.B., Rocha G.F.S., Sanches F.S.F., Oliveira F.N., Gobbi H. Comparative evaluation of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J. Clin. Pathol. 2008, 61:934-938.
28. Pantanowitz L., Sinard J.H., Henricks W.H., Fatheree L.A., Carter A.B., Contis L., Beckwith B.A., Evans A.J., Otis C.N., Lal A., Parwani A.V. Validating whole slide imaging for diagnostic purposes in pathology: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch. Pathol. Lab. Med. 2013, 1. (Epub ahead of print).
29. Park S., Pantanowitz L., Parwani A.V. Digital imaging in pathology. Clin. Lab Med. 2012, 32:557-584.
30. Park S.L., Pantanowitz L., Sharma G., Parwani A.V. Anatomic pathology laboratory information systems: a review. Adv. Anat. Pathol. 2012, 19:81-96.
31. Ricardo S.A., Milanezi F., Carvalho S.T., Leitão D.R., Schmitt F.C. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J. Clin. Pathol. 2007, 60:1001-1005.
32. Rocha R., Vassallo J., Soares F., Miller K., Gobbi H. Digital slides: present status of a tool for consultation, teaching, and quality control in pathology. Pathol Res Pract. 2009, 205:735-741.
33. Ross J.S. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect. 2009, 22:93-106.
34. Schiavon B.N., Jasani B., de Brot L., Vassallo J., Damascena A., Cirullo-Neto J., Ivanildo Neves J., Augusto Soares F., Gobbi H., Malagoli Rocha R. Evaluation of Reliability of FISH Versus Brightfield Dual-probe in situ Hybridization (BDISH) for Frontline Assessment of HER2 Status in Breast Cancer Samples in a Community Setting. Influence of Poor Tissue Preservation. Am. J. Surg. Pathol. 2012, 36:1489-1496.
35. Shah S., Chen B. Testing for HER2 in breast cancer: a continuing evolution. Pathol. Res. Int. 2010, 6:2011. 903202.
36. Skaland I., Ovestad I., Janssen E.A., Klos J., Kjellevold K.H., Helliesen T., Baak J.P. Digital image evaluation improves the quality of subjective HER-2 expression scoring in breast cancer. Appl. Immunohistochem. Mol. Morphol. 2008, 16:185-190.
37. Słodkowska J., Filas V., Buszkiewicz E., Trzeciak P., Wojciechowski M., Koktysz R., Staniszewski W., Breborowicz J., Rojo M.G. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images evaluation systems: ACIS III [Dako] and ScanScope [Aperio]. Folia Histochem. Cytobiol. 2010, 48:19-25.
38. Stathonikos N., Veta M., Huisman A., van Diest P.J. Going fully digital: perspective of a Dutch academic pathology lab. J. Pathol. Inform. 2013, 4:15.
39. Thomson T.A., Hayes M.M., Spinelli J.J., Hilland E., Sawrenko C., Phillips D., Dupuis B., Parker R.L. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod. Pathol. 2001, 14:1079-1086.
40. Weinstein R.S., Graham A.R., Richter L.C., Barker G.P., Krupinski E.A., Lopez A.M., Erps K.A., Bhattacharyya A.K., Yagi Y., Gilbertson J.R. Overview of telepathology, WSI microscopy, and whole slide imaging: prospects for the future. Hum. Pathol. 2009, 40:1057-1069.
41. Wilbur D.C., Madi K., Colvin R.B., Duncan L.M., Faquin W.C., Ferry J.A., Frosch M.P., Houser S.L., Kradin R.L., Lauwers G.Y., Louis D.N., Mark E.J., Mino-Kenudson M., Misdraji J., Nielsen G.P., Pitman M.B., Rosenberg A.E., Smith R.N., Sohani A.R., Stone J.R., Tambouret R.H., Wu C.L., Young R.H., Zembowicz A., Klietmann W. Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch. Pathol. Lab. Med. 2009, 133:1949-1953.
42. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F., American Society of Clinical Oncology; College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
43. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., Allred D.C., Bartlett J.M., Bilous M., Fitzgibbons P., Hanna W., Jenkins R.B., Mangu P.B., Paik S., Perez E.A., Press M.F., Spears P.A., Vance G.H., Viale G., Hayes D.F. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J. Clin. Oncol. 2013, (Epub ahead of print). 10.5858/arpa.2013-0953-SA.